Intranasal treatment with the mitochondria-targeted slow hydrogen sulfide releasing donor AP39 prevents inflammation-induced airway hyperreactivity in mice

Y. Karaman-Kutluay (Ankara, Turkey), Y. Kaya-Yasar (Trabzon, Turkey), T. Bozkurt (Ankara, Turkey), S. Celik Onder (Ankara, Turkey), I. Sahin-Erdemli (Ankara, Turkey)

Source: International Congress 2019 – Advances in asthma pharmacology
Session: Advances in asthma pharmacology
Session type: Poster Discussion
Number: 3879

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Karaman-Kutluay (Ankara, Turkey), Y. Kaya-Yasar (Trabzon, Turkey), T. Bozkurt (Ankara, Turkey), S. Celik Onder (Ankara, Turkey), I. Sahin-Erdemli (Ankara, Turkey). Intranasal treatment with the mitochondria-targeted slow hydrogen sulfide releasing donor AP39 prevents inflammation-induced airway hyperreactivity in mice. 3879

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: